Area of research
Oncology · Genetics
Research interest
Research interests include CAR-T cell therapy research, Virus-based gene therapy research, Cancer Research and Treatments, and Immunotherapy and Immune Responses.
Abstract 7814: Ganglioside targeting: Exerting sweet revenge on neuroblastoma
Immunotherapy-related cognitive impairment after CAR T cell therapy in mice
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis
Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum
CTIM-05. HUMANIZED ANTI-CAR ANTIBODIES AFFECT DURABLE RESPONSE TO GD2-CAR T-CELLS IN DIFFUSE MIDLINE GLIOMA
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Engineered CD47 protects T cells for enhanced antitumour immunity
Content-aware frame interpolation (CAFI): deep learning-based temporal super-resolution for fast bioimaging
Author Correction: Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Orientation-dependent CD45 inhibition with viral and engineered ligands
Tumor inflammation-associated neurotoxicity
Abstract 959: Immune signatures of GD2 CAR T cell activity in H3K27M+ diffuse midline glioma patients
IMMU-05. TUMOR INFLAMMATION-ASSOCIATED NEUROTOXICITY (TIAN): A TOXICITY SYNDROME IN PATIENTS TREATED WITH IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS
COMPARATIVE ACCURACY OF ALTERNATIVE EARLY MEASURES OF RESIDUAL DISEASE AFTER CAR19 THERAPY OF RELAPSED/REFRACTORY LBCL
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication
Enhanced safety and efficacy of protease-regulated CAR-T cell receptors
Enhanced T cell effector activity by targeting the Mediator kinase module
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1
Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity
NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity
Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins
Abstract CT031: GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas
DETERMINANTS OF RESISTANCE TO ENGINEERED T‐CELL THERAPIES TARGETING CD19 IN LYMPHOMA
OMIC-11. SINGLE CELL RNA SEQUENCING FROM THE CSF OF SUBJECTS WITH H3K27M+ DIPG/DMG TREATED WITH GD2 CAR T-CELLULAR THERAPY
Tuning the Antigen Density Requirement for CAR T-cell Activity